Clinical trial - The effects of an anti-IL-13 human monoclonal antibody, IMA-638, on allergen-induced airway responses in subjects with mild atopic asthma
Symposium Chairs: R. Djukanovic (Southampton, United Kingdom), M. Humbert (Clamart, France)
Aims: To describe the biology of interleukin (IL)-13, and to evaluate the allergen inhalation challenge for proof-of-concept studies, as well as the safety and efficacy of an anti-IL-13 human monoclonal antibody (hmAb) in an allergen challenge model of allergic asthma.
An abstract on this clinical trial is included in the Abstract Book (PDF version only, available during and after the ERS 2008 Congress).